Senestech, INC

SenesTech, Inc. announced its active online subscriber base more than doubled in Q2 2026, driven by a 186% growth in its e-commerce business.

SenesTech, Inc. held its 2026 annual meeting of stockholders, where directors were elected, executive compensation was approved advisory, and an amendment to the equity incentive plan was ratified.

SenesTech, Inc. announced its first quarter 2026 financial results, highlighting a 2% revenue increase to $493,000, driven by significant growth in direct-to-consumer and subscription channels despite a planned reduction in third-party e-commerce revenue.

SenesTech, Inc. announces the retirement of CEO Joel L. Fruendt and the appointment of Jamie Bechtel as Interim Executive Chair.

SenesTech, Inc. announced the retirement of CEO Joel L. Fruendt and the appointment of Jamie Bechtel as Interim Executive Chair.

SenesTech, Inc. has formalized the appointment of Michael Edell as Interim Chief Operating Officer with a six-month employment agreement.

SenesTech, Inc. reported a 43% increase in third-quarter revenue, driven by strong adoption of its Evolve fertility control products, and announced that it has alleviated substantial doubt about its ability to continue as a going concern.

SenesTech, Inc. reported a 36% increase in net revenue for Q2 2025, driven by strong adoption of its Evolve product line, while reducing its net loss.

SenesTech, Inc. reports a 17% increase in net revenue for the first quarter of 2025, driven by the success of its Evolve product line, while still facing operating losses and a need for additional financing.

SenesTech's Q3 2024 results show a significant revenue increase driven by the launch of their new Evolve product line, despite ongoing operating losses.

SenesTech's Q2 2024 results show a significant revenue increase driven by the launch of new products, Evolve and Evolve Mouse, despite ongoing operating losses.

SenesTech's first quarter 2024 results show a significant increase in revenue compared to the same period last year, primarily driven by the launch of their new product, Evolve.

SenesTech's FY2024 revenue increased by 56% driven by the launch of its Evolve product line, while the company continues to manage operating losses.

SenesTech, Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information and a new executive officer clawback policy.

SenesTech, Inc. released its 2023 annual report, highlighting a focus on commercializing its fertility control products, ContraPest and Evolve, while navigating financial challenges.

Glenbrook Capital Management reported changes in beneficial ownership of SenesTech, Inc. common stock on July 20, 2026.

Michael Edell, CEO and Director of SenesTech, Inc., acquired 1,000 shares of common stock.

Glenbrook Capital Management reports a significant acquisition of common stock in SenesTech, Inc., increasing its beneficial ownership.

Glenbrook Capital Management reports increased beneficial ownership of SenesTech, Inc. common stock through multiple open market purchases.

Joshua Matthew Moss, a Director at SenesTech, Inc., acquired 100,000 stock options with an exercise price of $1.65, exercisable starting July 15, 2026.

Phillip Nicholas Grandinetti III, a Director at SenesTech, Inc., acquired 100,000 stock options.

SenesTech, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect directors, vote on executive compensation, and approve an amendment to its 2018 Equity Incentive Plan.

SenesTech, Inc. has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

SenesTech is asking stockholders to approve a reverse stock split, an amendment to its equity incentive plan, and other proposals at its upcoming annual meeting.

SenesTech, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

SenesTech is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Glenbrook Capital Management has filed a Schedule 13D, reporting beneficial ownership of 19.95% of SenesTech, Inc. common stock, acquired for investment purposes.

Glenbrook Capital Management has increased its beneficial ownership in SenesTech, Inc. to 11.4% of outstanding common stock.

Glenbrook Capital Management has filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in SenesTech, Inc., including shares underlying warrants with ownership blockers.

PFS Cap Mgt Co and PFS Trust have disclosed a 9.99% beneficial ownership stake in SenesTech, Inc., including shares from warrants subject to a 9.99% blocker.

Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.9% in SenesTech, Inc., limited by warrant exercise provisions.

PFS Cap Mgt Co and PFS Trust have filed an amended Schedule 13G, reporting a 5.2% beneficial ownership stake in SenesTech, Inc., totaling 90,507 shares of common stock.

Lind Global Fund II LP, along with its affiliates Lind Global Partners II LLC and Jeff Easton, has filed an amended Schedule 13G, confirming a continued passive beneficial ownership of 9.9% in SenesTech, Inc. as of December 31, 2024.